Servatus raises $7.5 million to advance autoimmune therapies with its microbial biotherapeutics clinical programs
- Written by PR Newswire
- Servatus has raised $7.5 million in an oversubscribed capital raise, with strong support from sophisticated shareholders
- Funds raised will underpin Servatus' live microbial and engineered protein biotherapeutics drug development
- Two Phase 1/2 clinical trials to launch shortly in Queensland, for insomnia and rheumatoid arthritis, complementing...
